What the business is, and whether it's a good one at a fair price.
Manufactures and sells specialty ingredients and pharmaceutical, food and nutrition excipients through two reporting segments. The Pharmaceutical, Food and Nutrition segment earned ₹362.6 crore in FY26, supplying ingredients used in pharma, food, and nutrition formulations. The Speciality Ingredients segment earned ₹279.6 crore, having grown 62% year-on-year, and includes the newly launched AbsorBis bisglycinate brand targeting roughly a $1 billion global market at about 4x the realisation of the core portfolio. Materials are the largest cost line at 42% of revenue, with management citing phosphoric and sulphuric acid inflation as a key FY26 headwind, followed by other opex at 22% and employee costs at 8.1%. The company is also building a battery-grade iron phosphate business for LFP batteries, with a Phase 1 plant of 25,000 MT per year at Dahej targeted for April 2027 commissioning, a 42-customer qualification pipeline, 6 customers in commercial validation, and an initial 700 MT purchase order. The company listed on the exchanges on 28 November 2025 and acquired 85% of Ireland-based Nutrition Supplies Services to strengthen its European presence.
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SUDEEP PHARMA LIMITED's filed financials and exchange disclosures
SUDEEP PHARMA LIMITED is a Chemicals & Petrochemicals company listed on NSE and BSE, trading under the symbol SUDEEPPHRM.
Yes. Over the trailing twelve months SUDEEP PHARMA LIMITED reported a net profit of ₹184 Cr on revenue of ₹676 Cr.
Not in the latest reported year — SUDEEP PHARMA LIMITED's dividend payout for FY26 was nil.
No. Debt stands at 0.17× equity, and it carries net debt of ₹122 Cr. That is lower than 51% of its 101 Specialty Chemicals peers.
On trailing P/E, SUDEEP PHARMA LIMITED ranks 89 of 103 in Specialty Chemicals — cheaper than 14% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
On a typical session SUDEEP PHARMA LIMITED moves 1.70% — that is the median absolute close-to-close move across its last 194 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SUDEEP PHARMA LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
